Tirzepatide 3-month results: what TikTok shows vs. clinical data

What's this video probably claiming?

Based on the caption "3 meses después" (3 months later) paired with the hashtags #bajardepeso, #trizepatide, and #glp1, this is almost certainly a before-and-after weight loss testimonial. The creator appears to be documenting personal results from tirzepatide use over a 90-day period, likely showing visible body composition changes and framing them as evidence the drug works. The hashtag #bajardepesonatural is interesting here because tirzepatide is anything but a purely "natural" intervention, which either reflects loose hashtag strategy for reach or suggests the creator is downplaying the pharmaceutical nature of what they're taking. Three months is also a carefully chosen window: it's long enough to show meaningful results, short enough to avoid the harder conversations about what happens after that.

What does the science actually show?

Tirzepatide's efficacy data is genuinely strong, and pretending otherwise would be dishonest. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) enrolled 2,539 adults with obesity and no diabetes. At 72 weeks, participants on the highest dose (15 mg weekly) lost a mean of 20.9% of body weight versus 3.1% on placebo. At the three-month mark, participants were still dose-escalating, typically sitting at 5 mg or 7.5 mg, and average weight loss at that stage was roughly 8-10% depending on the dose arm. So if a creator is showing dramatic physical transformation at 90 days, the math is possible but likely represents an above-average responder, not a typical outcome. The drug works through dual GIP and GLP-1 receptor agonism, which appears to produce larger weight loss than GLP-1-only agents like semaglutide in head-to-head data (SURMOUNT-5, 2025, NEJM).

Where does the social media noise diverge from clinical reality?

Several gaps exist between what testimonial content implies and what the clinical record shows. First, three-month snapshots erase the side effect story. In SURMOUNT-1, gastrointestinal adverse events (nausea, vomiting, diarrhea) occurred in roughly 80% of participants during dose escalation, with about 4.3% discontinuing due to GI issues. You rarely see that in the show reel. Second, weight regain after stopping tirzepatide is substantial. The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) showed participants who discontinued after 36 weeks regained about two-thirds of their lost weight within a year. Third, the #bajardepesonatural framing misrepresents the intervention as lifestyle-adjacent when tirzepatide is a prescription drug with a real contraindication list including personal or family history of medullary thyroid carcinoma and MEN2. That context disappears entirely in before-and-after content.

What should you actually know?

Tirzepatide produces real, clinically meaningful weight loss for many people, and it would be paternalistic to pretend the drug doesn't work. But individual testimonials carry almost no predictive value for your own outcome. Responder rates vary considerably: some participants in SURMOUNT-1 lost more than 25% of body weight, while others lost less than 5%. Age, baseline metabolic health, adherence to dose escalation schedules, diet quality, and sleep all appear to influence outcomes. Cost and access remain real barriers: branded tirzepatide (Zepbound) can exceed $1,000 per month without insurance coverage. Compounded versions circulate widely, but compounded tirzepatide is not equivalent to FDA-approved Zepbound and carries different manufacturing oversight. Anyone considering this medication should be evaluated by a licensed clinician who can review contraindications, monitor labs, and manage the inevitable side effects during escalation.